Neurology

Essential Pharma and AcedrA Biopharmaceuticals sign Distribution Agreement to commercialize essential medicines in the Middle East and North Africa region

Retrieved on: 
Tuesday, March 26, 2024
Neurology, Essential, Partnership, Risk, Patient, Conditional sentence, Medication, Pharmaceutical industry

This strategic collaboration aims to address unmet commercial and medical needs by allowing AcedrA to register, promote, and commercialize a portfolio of 36 Essential Medicines across various therapeutic areas within 12 countries in the Middle East and North Africa Region.

Key Points: 
  • This strategic collaboration aims to address unmet commercial and medical needs by allowing AcedrA to register, promote, and commercialize a portfolio of 36 Essential Medicines across various therapeutic areas within 12 countries in the Middle East and North Africa Region.
  • Essential Pharma specializes in ensuring sustainable access to clinically differentiated, low-volume, and difficult-to-manufacture medicines for chronic diseases and acute care.
  • As a global leader in acquiring, integrating, and maintaining Essential medicines at risk of shortages or discontinuation, Essential Pharma works collaboratively with partners worldwide to uphold the highest standards of pharmaceutical manufacturing.
  • Emma Johnson, CEO of Essential Pharma, commented: “As we continue our mission to provide sustainable access to vital medicines, we are thrilled to announce our partnership with AcedrA BioPharmaceuticals.

Tetricus Labs Partners with Silver Hill Hospital on Research to Advance Precision Psychiatry

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Technology, Other Health, Health, Neurology, Mental Health, Research, Software, Artificial Intelligence, Hospitals, Science, Dow, Panic disorder, Psychiatry, Data science, Associate, Silver, Partnership, Patient, Tetricus, Bipolar disorder, Radiology, Neuroscience, Doctor of Philosophy, DSM-IV codes, Evercore, MD, Psychology, Silver Hill Hospital, Social anxiety disorder, Machine learning, Medical director, Yale University, Medicine, Nursing

Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.

Key Points: 
  • Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.
  • “We're patient-founded, patient-owned, and patient-run,” said Dow, CEO for Tetricus Labs.
  • Andrew J. Gerber, MD, PhD, President and Medical Director of Silver Hill Hospital, will join Tetricus Labs as a Medical Advisor to ensure Tetricus’ machine learning software is designed to fit within the busy workflow of hospital clinicians and staff, maximizing its accessibility for providers and potential impact on patient outcomes.
  • “This partnership represents our continued commitment to exploring innovative methods that can enhance our understanding of psychiatric disorders and improve patient outcomes."

Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology

Retrieved on: 
Tuesday, April 9, 2024
Health, Other Science, General Health, Clinical Trials, Research, Science, Pharmaceutical, Hypersensitivity, Anaphylaxis, Angioedema, Brain, Eptinezumab, Virtual Private LAN Service, Headache, Patient, American Academy, Interview, MD, Neurology, Migraine, Lundbeck, Quality of life, AAN, Abstract, Pharmaceutical industry

These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.

Key Points: 
  • These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.
  • “Our real-world data helps us better understand how individuals are uniquely impacted by migraine beyond monthly headache days.
  • We’re excited to continually partner with the migraine community to raise the bar on preventive treatment expectations.”
    VYEPTI is indicated for the preventive treatment of migraine in adults.
  • The safety and efficacy of VYEPTI has not been evaluated for use in any psychiatric conditions.

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Monday, April 8, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Inflammation, Therapy, Conference

Ventus Therapeutics, Inc. , a clinical-stage biopharmaceutical company utilizing its deep protein science expertise and proprietary computational chemistry platform, ReSOLVE™, to develop novel small molecule therapeutics for immunology, inflammation, and neurology disorders, announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, being held April 16-17 in Toronto.

Key Points: 
  • Ventus Therapeutics, Inc. , a clinical-stage biopharmaceutical company utilizing its deep protein science expertise and proprietary computational chemistry platform, ReSOLVE™, to develop novel small molecule therapeutics for immunology, inflammation, and neurology disorders, announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, being held April 16-17 in Toronto.
  • Dr. Bigal will be presenting on April 16th at 11:30 AM ET.

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Monday, April 8, 2024
Mental Health, Research, Neurology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, SIRS, Schizophrenia, Medication, Clozapine, XETRA, Incidence, Patient, CNS, Peripheral nervous system, Safety, TRS, Schizophrenia International Research Society, Pharmaceutical industry

The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.

Key Points: 
  • The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.
  • As previously announced by Newron, the study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.
  • Treatment with evenamide was associated with sustained, clinically significant benefit that increased throughout the one-year course of treatment.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid).

Alzheon Announces that United States Federal Circuit Affirmed Decision of U.S. Patent Office Invalidating Risen (Suzhou) Pharmaceutical Technology Co., Ltd.’s Patent on Isotopically Enriched Forms of ALZ-801/Valiltramiprosate

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Professional Services, Health, Patent Law, Pharmaceutical, Neurology, Research, Genetics, Legal, Science, Clinical Trials, Comment, Patent, Patient, NDA, PTAB, Federal Circuit Court, Doctor of Philosophy, IPR, Prodrug, Rule 34, Pharmaceutical industry

The decision was affirmed without discussion by the Federal Circuit Court (Case No.

Key Points: 
  • The decision was affirmed without discussion by the Federal Circuit Court (Case No.
  • In 2020, Alzheon petitioned the Patent Trial and Appeal Board (PTAB) of the U.S. Patent Office (USPTO) to institute an Inter-Parties Review (IPR) of Risen’s U.S. Patent No.
  • Risen appealed the PTAB’s decision to the United States Court of Appeals for the Federal Circuit.
  • “Alzheon is pleased that the U.S. Federal Circuit affirmed the Patent Trial and Appeal Board’s decision to invalidate all claims of Risen’s patent.

SpineX Closes Recruitment for SCONE™ Clinical Trial

Retrieved on: 
Monday, April 8, 2024
Children, Biotechnology, FDA, Health, Neurology, Health Technology, Medical Devices, Research, Consumer, Science, Clinical Trials, Cord, Brain, Cerebral palsy, Multiple sclerosis, SCIP, Patient, Stroke, Clinical trial, Urinary bladder, Trial of the century, Skin, Spinal cord, Heart, Urinary incontinence, Cauda equina syndrome, Neuromodulation, Pharmaceutical industry

SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.

Key Points: 
  • SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.
  • The clinical trial— Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Clinical Study — began in May 2022.
  • “SCONE has the power to transform the lives of millions of patients with neurogenic bladder,” says Parag Gad, SpineX co-founder & CEO.
  • SpineX anticipates beginning a multi-center pivotal trial for children with Cerebral Palsy in 2024.

Synchron Launches Patient Registry for Stentrode Brain Computer Interface

Retrieved on: 
Monday, April 8, 2024
Medical Devices, Health, Neurology, Health Technology, Other Health, Biotechnology, Brain, BCI, Motor cortex, Communication, Patient, UPMC, University, Disability studies, Movement, Physician, Pathology, Medical device

The Synchron BCI represents a novel approach to restoring functionality in patients with limited mobility.

Key Points: 
  • The Synchron BCI represents a novel approach to restoring functionality in patients with limited mobility.
  • By leveraging the natural highways of the brain, an individual’s blood vessels, the device is implanted in the brain without the need for invasive brain surgery.
  • “We are thrilled to launch our community-centered BCI registry,” said Tom Oxley, CEO & Founder, Synchron.
  • For more information about the Synchron BCI and our registry, visit https://synchronbci.com .

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

Retrieved on: 
Monday, April 8, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Epilepsy, Plasma, LGND, Conference, UMN, Seizure, Status epilepticus, Patient, Topiramate, Orphan, Pharming, Concomitant, Pharmacokinetics, University, Faculty, Safety, Poster, Food, Pharmaceutical industry

The poster was featured at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference in London, England.

Key Points: 
  • The poster was featured at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference in London, England.
  • The authors presented modeling and simulations of IV topiramate dosing based on previous studies conducted by UMN faculty in healthy research participants and patients.
  • Ligand licensed the rights to the IV formulation of topiramate from UMN and entered into a global license agreement with CURx Pharmaceuticals to further develop and commercialize the product.
  • “The availability of an injectable topiramate formulation will make it possible to ensure continuity of therapy.